

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.

陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

XTL6001 RESEARCH ACCEPTED FOR PRESENTATIONS AT EASD 2026 AND ASN KIDNEY WEEK 2026

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that research results relating to XTL6001, one of the Group’s key products, have been accepted for presentation at multiple leading internationally recognised academic conferences in the fields of diabetes, metabolic diseases and nephrology. Following the initial presentation at the ADA, additional analysis will be featured at the upcoming EASD and ASN annual meetings.

- (i) two research abstracts relating to XTL6001 have been accepted for presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (“**EASD 2026**”). The research entitled “XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for weight loss and obesity-related complications” has been selected for an oral presentation under the session entitled “Future obesity treatments in human trials”, while the research entitled “XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for chronic kidney disease/diabetic kidney disease with proteinuria and hyperuricaemia” has been selected for a short oral discussion presentation; and
- (ii) a research abstract entitled “XTL6001: A Novel Triple MasR/GCGR/GLP-1 Receptor Agonist for Hyperuricemic Nephropathy” has been accepted for poster presentation at the American Society of Nephrology Kidney Week 2026 (“**ASN Kidney Week 2026**”) under the session entitled “CKD: Mechanisms of Injury and Fibrosis – 1”.

About EASD Annual Meeting and ASN Kidney Week

The EASD Annual Meeting is one of the major international academic conferences in the field of diabetes and metabolic diseases, providing an important platform for experts and researchers worldwide to exchange views on the latest scientific advances, clinical research and therapeutic developments in diabetes and related metabolic diseases. Oral presentations at the EASD Annual Meeting are selected by its Scientific Programme Committee based on the review of submitted abstracts. EASD 2026 will be held in Milan, Italy from September 28 to October 2, 2026.

ASN Kidney Week is one of the influential international academic conferences in the field of kidney diseases worldwide, providing an important academic platform for experts, clinicians and researchers worldwide to exchange views on the latest developments in basic research, clinical research and the diagnosis and treatment of kidney diseases. ASN Kidney Week 2026 will be held in Denver, Colorado, the United States, from October 21 to 25, 2026.

Research results relating to the Group's core product MT1013 were previously selected for presentation in the Late-Breaking Research Posters session at ASN Kidney Week 2025. The Company believes that the further selection of research relating to XTL6001 by ASN Kidney Week 2026 reflects continued international academic interest in the Group's innovative research in kidney diseases.

About XTL6001

XTL6001 is one of the Group's key products and a GLP-1R/GCGR/MasR tri-target agonist that has received IND approval in both the PRC and the U.S. By innovatively incorporating MasR as a third target in addition to GLP-1R and GCGR, XTL6001 features a differentiated tri-target mechanism, with potential benefits extending beyond the weight and metabolic effects typically associated with GLP-1-based therapies to include renal protection. The Group is developing XTL6001 for weight management for obesity or overweight, proteinuric CKD and MASH. As set out in the prospectus of the Company, the Phase I clinical trial of XTL6001 in China had completed the last patient last visit and database lock. The Group plans to continue advancing the clinical development of XTL6001 in accordance with its disclosed development plan.

As previously presented at the 86th Scientific Sessions of the American Diabetes Association ("ADA 2026"), preclinical and Phase I clinical data of XTL6001 demonstrated its potential across weight management, metabolic regulation and renal protection. In the weight management and metabolic setting, XTL6001 demonstrated reductions in body weight, waist circumference and serum uric acid, together with improvements in lipid profiles. In preclinical kidney disease models, XTL6001 demonstrated reductions in urinary albumin and improvements in renal function-related parameters.

The Company believes that, following the presentation of the research results relating to XTL6001 at ADA 2026, the subsequent selection of such research results for an oral presentations at EASD 2026 in the fields of weight management and CKD/DKD, respectively, and for a poster presentation at ASN Kidney Week 2026 in the field of hyperuricemic nephropathy represents another important milestone in the development of XTL6001. The selection of XTL6001 studies for presentation at major international academic meetings in both the diabetes/metabolic and nephrology fields further highlights its differentiated development profile beyond weight management alone, and underscores the potential renal protective effects of its innovative GLP-1R/GCGR/MasR tri-target mechanism, distinguishing XTL6001 from conventional GLP-1-based therapies.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 17 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.